Cancer News

Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma (01/05/2017)

Among patients with advanced follicular lymphoma who have not received prior therapy, treatment with Gazyva® (obinutuzumab) plus chemotherapy delays cancer progression compared to the standard Rituxan® (rituximab) plus chemotherapy, and should now be considered an option as first-line therapy for patients with this disease. These results were recently presented at the 2016 annual meeting of …

Continue reading "Gazyva® Delays Cancer Progression as Initial Therapy in Advanced Follicular Lymphoma"

Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma (12/15/2016)

Treatment including the targeted agent Gazyva (obinutuzumab) delays cancer progression for a longer period of time than treatment with Rituxan (rituximab) among patients with follicular lymphoma who have not received prior therapy. These results were recently presented at a plenary session of the 2016 annual meeting of the American Society of Hematology (ASH). Follicular lymphoma … Continue reading "Gazyva® Improves Outcomes Compared to Rituxan® in Untreated Follicular Lymphoma"

CAR Therapy Effective in Advanced Lymphoma (06/20/2016)

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types … Continue reading "CAR Therapy Effective in Advanced Lymphoma"